{"id":45569,"date":"2025-11-03T11:29:00","date_gmt":"2025-11-03T03:29:00","guid":{"rendered":"https:\/\/flcube.com\/?p=45569"},"modified":"2025-11-03T11:29:01","modified_gmt":"2025-11-03T03:29:01","slug":"simnovas-dll3%e2%80%91targeted-car%e2%80%91t-snc115-wins-first%e2%80%91in%e2%80%91china-clinical%e2%80%91trial-approval-for-relapsed-sclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45569","title":{"rendered":"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC"},"content":{"rendered":"\n<p><strong>Shanghai Simnova Biotech Co., Ltd.<\/strong> announced that its self\u2011developed anti\u2011DLL3 chimeric antigen receptor T\u2011cell (CAR\u2011T) injection, <strong>SNC115<\/strong>, has received formal <strong>clinical\u2011trial approval<\/strong> from the <strong>National Medical Products Administration (NMPA)<\/strong>. The IND clearance paves the way for a first\u2011in\u2011China study of a DLL3\u2011directed CAR\u2011T therapy in patients with <strong>relapsed or refractory small\u2011cell lung cancer (SCLC)<\/strong> and other neuroendocrine malignancies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>SNC115 \u2013 anti\u2011DLL3 CAR\u2011T cell injection<\/td><\/tr><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>NMPA clinical\u2011trial approval (IND) \u2013 30\u202fOct\u202f2025<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed\/refractory SCLC and selected neuroendocrine cancers<\/td><\/tr><tr><td><strong>Target Rationale<\/strong><\/td><td>DLL3 is highly expressed on tumor cells but minimally on normal tissue, offering a high therapeutic index<\/td><\/tr><tr><td><strong>First\u2011in\u2011China<\/strong><\/td><td>First DLL3\u2011targeted CAR\u2011T product cleared for clinical development in the Chinese market<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Multicenter Phase\u202fI\/II, dose\u2011escalation followed by expansion; primary endpoints: safety, tolerability, objective response rate<\/td><\/tr><tr><td><strong>Timeline<\/strong><\/td><td>First patient in (FPI) expected Q1\u202f2026; data read\u2011out anticipated late 2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-dll3\">Why DLL3?<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tumour\u2011Specific Expression<\/strong> \u2013 DLL3 is a Notch\u2011pathway ligand that is over\u2011expressed on >\u202f80\u202f% of SCLC cells while virtually absent in healthy adult tissues.<\/li>\n\n\n\n<li><strong>Therapeutic Window<\/strong> \u2013 The stark differential expression makes DLL3 an ideal antigen for CAR\u2011T targeting, reducing off\u2011tumour toxicity.<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong> \u2013 Relapsed\/refractory SCLC has a 5\u2011year survival &lt;\u202f5\u202f%; current options are limited to chemotherapy and limited\u2011duration immunotherapy.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-simnova\">About Simnova<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2019 as a Simcere Pharmaceutical subsidiary; spun off as an independent biotech in 2021.<\/li>\n\n\n\n<li><strong>R&amp;D Footprint:<\/strong> Dual research hubs in Shanghai (China) and Boston (USA).<\/li>\n\n\n\n<li><strong>Pipeline Focus:<\/strong> Cell\u2011based immunotherapies for solid tumours, with a particular emphasis on novel tumor\u2011associated antigens (DLL3, B7\u2011H3, etc.).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-path\">Clinical Development Path<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Phase\u202fI Dose\u2011Escalation<\/strong> \u2013 Establish maximum tolerated dose (MTD) and assess cytokine release syndrome (CRS) profile.<\/li>\n\n\n\n<li><strong>Phase\u202fII Expansion<\/strong> \u2013 Enroll up to 60 patients with SCLC or neuroendocrine tumors; evaluate objective response rate (ORR) and duration of response (DoR).<\/li>\n\n\n\n<li><strong>Regulatory Strategy<\/strong> \u2013 Parallel submission for accelerated approval pathways (China\u2019s \u201cPriority Review\u201d and potential U.S. IND filing in 2026).<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook\">Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Oncology Landscape<\/strong> \u2013 CAR\u2011T therapies for hematologic malignancies have already captured >\u202f$1\u202fB in sales; solid\u2011tumor CAR\u2011T is the next frontier.<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong> \u2013 Analysts estimate a peak\u2011year market of <strong>$500\u202fM\u2013$800\u202fM<\/strong> for a successful DLL3\u2011CAR\u2011T in SCLC, given the high incidence (>\u202f30,000 new cases annually in China).<\/li>\n\n\n\n<li><strong>Strategic Partnerships<\/strong> \u2013 Simnova may seek co\u2011development or licensing deals with global pharma to expand SNC115 beyond China.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements that involve risks and uncertainties, including regulatory approvals, clinical trial outcomes, and commercial prospects. Actual results may differ materially from those expressed herein.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Simnova Biotech Co., Ltd. announced that its self\u2011developed anti\u2011DLL3 chimeric antigen receptor T\u2011cell (CAR\u2011T)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45570,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,21,77,62,3260],"class_list":["post-45569","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-car-t","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-simnova-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Simnova Biotech Co., Ltd. announced that its self\u2011developed anti\u2011DLL3 chimeric antigen receptor T\u2011cell (CAR\u2011T) injection, SNC115, has received formal clinical\u2011trial approval from the National Medical Products Administration (NMPA). The IND clearance paves the way for a first\u2011in\u2011China study of a DLL3\u2011directed CAR\u2011T therapy in patients with relapsed or refractory small\u2011cell lung cancer (SCLC) and other neuroendocrine malignancies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45569\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC\" \/>\n<meta property=\"og:description\" content=\"Shanghai Simnova Biotech Co., Ltd. announced that its self\u2011developed anti\u2011DLL3 chimeric antigen receptor T\u2011cell (CAR\u2011T) injection, SNC115, has received formal clinical\u2011trial approval from the National Medical Products Administration (NMPA). The IND clearance paves the way for a first\u2011in\u2011China study of a DLL3\u2011directed CAR\u2011T therapy in patients with relapsed or refractory small\u2011cell lung cancer (SCLC) and other neuroendocrine malignancies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45569\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T03:29:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-03T03:29:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0305.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45569#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45569\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC\",\"datePublished\":\"2025-11-03T03:29:00+00:00\",\"dateModified\":\"2025-11-03T03:29:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45569\"},\"wordCount\":460,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45569#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0305.webp\",\"keywords\":[\"Cancer\",\"CAR-T\",\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"Simnova Biotech\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45569#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45569\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45569\",\"name\":\"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45569#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45569#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0305.webp\",\"datePublished\":\"2025-11-03T03:29:00+00:00\",\"dateModified\":\"2025-11-03T03:29:01+00:00\",\"description\":\"Shanghai Simnova Biotech Co., Ltd. announced that its self\u2011developed anti\u2011DLL3 chimeric antigen receptor T\u2011cell (CAR\u2011T) injection, SNC115, has received formal clinical\u2011trial approval from the National Medical Products Administration (NMPA). The IND clearance paves the way for a first\u2011in\u2011China study of a DLL3\u2011directed CAR\u2011T therapy in patients with relapsed or refractory small\u2011cell lung cancer (SCLC) and other neuroendocrine malignancies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45569#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45569\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45569#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0305.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0305.webp\",\"width\":1080,\"height\":608,\"caption\":\"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45569#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Simnova Biotech Co., Ltd. announced that its self\u2011developed anti\u2011DLL3 chimeric antigen receptor T\u2011cell (CAR\u2011T) injection, SNC115, has received formal clinical\u2011trial approval from the National Medical Products Administration (NMPA). The IND clearance paves the way for a first\u2011in\u2011China study of a DLL3\u2011directed CAR\u2011T therapy in patients with relapsed or refractory small\u2011cell lung cancer (SCLC) and other neuroendocrine malignancies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45569","og_locale":"en_US","og_type":"article","og_title":"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC","og_description":"Shanghai Simnova Biotech Co., Ltd. announced that its self\u2011developed anti\u2011DLL3 chimeric antigen receptor T\u2011cell (CAR\u2011T) injection, SNC115, has received formal clinical\u2011trial approval from the National Medical Products Administration (NMPA). The IND clearance paves the way for a first\u2011in\u2011China study of a DLL3\u2011directed CAR\u2011T therapy in patients with relapsed or refractory small\u2011cell lung cancer (SCLC) and other neuroendocrine malignancies.","og_url":"https:\/\/flcube.com\/?p=45569","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-03T03:29:00+00:00","article_modified_time":"2025-11-03T03:29:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0305.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45569#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45569"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC","datePublished":"2025-11-03T03:29:00+00:00","dateModified":"2025-11-03T03:29:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45569"},"wordCount":460,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45569#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0305.webp","keywords":["Cancer","CAR-T","Cell-therapy","Clinical trial approval \/ initiation","Simnova Biotech"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45569#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45569","url":"https:\/\/flcube.com\/?p=45569","name":"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45569#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45569#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0305.webp","datePublished":"2025-11-03T03:29:00+00:00","dateModified":"2025-11-03T03:29:01+00:00","description":"Shanghai Simnova Biotech Co., Ltd. announced that its self\u2011developed anti\u2011DLL3 chimeric antigen receptor T\u2011cell (CAR\u2011T) injection, SNC115, has received formal clinical\u2011trial approval from the National Medical Products Administration (NMPA). The IND clearance paves the way for a first\u2011in\u2011China study of a DLL3\u2011directed CAR\u2011T therapy in patients with relapsed or refractory small\u2011cell lung cancer (SCLC) and other neuroendocrine malignancies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45569#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45569"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45569#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0305.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0305.webp","width":1080,"height":608,"caption":"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45569#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simnova\u2019s DLL3\u2011Targeted CAR\u2011T (SNC115) Wins First\u2011In\u2011China Clinical\u2011Trial Approval for Relapsed SCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0305.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45569"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45569\/revisions"}],"predecessor-version":[{"id":45571,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45569\/revisions\/45571"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45570"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}